Immorna Biotherapeutics, Inc., a China-based clinical stage biotechnology company, announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application for JCXH-211 intravenous (IV), a novel, first-in-class self-replicating mRNA (srRNA) encoding the engineered human interleukin (IL)-12 protein.
The IND approval enables the company to commence a Phase 1/2, multi-centre, open-label, dose escalation and expansion study of JCXH-211, administered intravenously in patients with malignant solid tumours.
The aim of the study is to evaluate the safety and tolerability, and to determine the recommended Phase two dose (RP2D) for JCXH-211 IV along with checkpoint inhibitor (CPI), and to evaluate preliminary efficacy of the combination at the RP2D.
The product is a first-in-class lipid nanoparticle (LNP) encapsulated srRNA, utilising Immorna's proprietary technology, encoding the engineered human IL-12 protein.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA